The 33-Mer Gluten Peptide: Why This Fragment Is So Toxic in Celiac Disease | Research

The takeaway

A 33-amino-acid peptide naturally produced from wheat gluten digestion is an exceptionally potent immune trigger in celiac disease because it packs six T cell epitopes, binds strongly to HLA-DQ2, and needs no further processing to activate immune cells.

6 T cell epitopes in 33 amino acids
The 33-mer gliadin peptide contains six overlapping copies of three celiac disease T cell epitopes — an unusually dense concentration of immune targets in a single digestive fragment

What the researchers found

A 33-amino-acid gliadin peptide (the '33-mer'), naturally produced by gastrointestinal digestion of wheat gluten, is an exceptionally potent T cell stimulator in celiac disease. It contains six overlapping copies of three T cell epitopes and, after modification by tissue transglutaminase (TG2), binds with high affinity to the HLA-DQ2 immune molecule. Remarkably, the 33-mer doesn't need to be further processed inside immune cells — it can be presented to T cells directly, even by chemically fixed (non-living) antigen-presenting cells. It also binds DQ2 optimally at pH 6.3, promoting extracellular binding.

Why it matters

This study revealed why one specific peptide fragment from wheat gluten is so toxic to people with celiac disease. The 33-mer is uniquely resistant to digestion, contains multiple T cell epitopes packed into a single fragment, and doesn't need immune cell processing to trigger an attack. Understanding this 'super-antigen' peptide has been central to developing celiac disease therapies, including enzyme supplements designed to break it down and peptide-based tolerance therapies.

The numbers in context

33 amino acids · 6 overlapping T cell epitopes (3 types) · Optimal DQ2 binding at pH 6.3 · More potent than 12-mer control · No intracellular processing required

How the study worked

In vitro immunology study using T cells derived from celiac disease intestinal biopsies. The 33-mer peptide was tested for DQ2 binding affinity, T cell stimulatory potency, and antigen-presenting cell (APC) requirements using live and glutaraldehyde-fixed EBV-transformed B cells and dendritic cells. Binding pH profiles were characterized.

Who was studied

T cells derived from celiac disease intestinal lesion biopsies; in vitro antigen presentation assays

What this study cannot tell us

In vitro study using celiac patient-derived T cells — does not address in vivo immune dynamics. Only HLA-DQ2-associated celiac disease studied (most but not all celiac patients carry DQ2). The study characterizes the 33-mer's properties but does not test therapeutic interventions.

How to read the evidence

This is a well-designed in vitro immunology study published in the Journal of Immunology by a leading celiac disease research group. The findings are mechanistically rigorous and have been widely replicated and built upon. While in vitro, the clinical relevance is well established through subsequent research.

When this study was published

Published in 2004, this is a foundational study in celiac disease research. The 33-mer concept it established has been validated repeatedly and remains central to current understanding and therapeutic development for celiac disease.

The bigger picture

The discovery of the 33-mer as the key immunotoxic fragment in celiac disease has driven multiple therapeutic approaches. Enzyme therapies like latiglutenase are being developed specifically to break down this resistant peptide. Peptide vaccine approaches (like Nexvax2, which was tested in clinical trials) used portions of the 33-mer to try to induce immune tolerance. Understanding this single peptide has been foundational to nearly every celiac disease therapeutic strategy developed since.

Questions still open

Can oral enzyme supplements effectively degrade the 33-mer before it reaches the immune cells in the intestine?
Could peptide-based tolerance therapy using modified versions of the 33-mer train the immune system to stop reacting to gluten?
Are there other immunodominant gluten peptides beyond the 33-mer that also need to be addressed for effective celiac therapy?

Common questions

Why can't your body break down this gluten peptide?

The 33-mer is packed with proline residues — an amino acid that human digestive enzymes are particularly bad at cutting through. The peptide adopts a rigid helical shape that resists breakdown, surviving intact through stomach acid and intestinal enzymes to reach the immune cells in the gut lining.

Is this the only gluten peptide that triggers celiac disease?

No, but it's the most potent. The 33-mer contains six overlapping immune targets and is the dominant trigger in most celiac patients who carry the HLA-DQ2 gene. Other gluten peptides can also trigger immune responses, which is why complete gluten avoidance — not just avoiding this one peptide — is necessary.

Read the original research

Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion.

Journal of immunology (Baltimore, Md. : 1950), 173(3), 1757-62

View on PubMed ↗

Citation

Qiao, Shuo-Wang; Bergseng, Elin; Molberg, Øyvind; Xia, Jiang; Fleckenstein, Burkhard; Khosla, Chaitan; Sollid, Ludvig M. (2004). Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion.. Journal of immunology (Baltimore, Md. : 1950), 173(3), 1757-62.